Literature DB >> 12704388

Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.

Gaël Nicolas1, Lydie Viatte, Dan-Qing Lou, Myriam Bennoun, Carole Beaumont, Axel Kahn, Nancy C Andrews, Sophie Vaulont.   

Abstract

Hereditary hemochromatosis is a prevalent genetic disorder of iron hyperabsorption leading to hyperferremia, tissue iron deposition and complications including cirrhosis, hepatocarcinoma, cardiomyopathy and diabetes. Most individuals affected with hereditary hemochromatosis are homozygous with respect to a missense mutation that disrupts the conformation of HFE, an atypical HLA class I molecule (ref. 1; OMIM 235200). Mice lacking Hfe or producing a C282Y mutant Hfe protein develop hyperferremia and have high hepatic iron levels. In both humans and mice, hereditary hemochromatosis is associated with a paucity of iron in reticuloendothelial cells. It has been suggested that HFE modulates uptake of transferrin-bound iron by undifferentiated intestinal crypt cells, thereby programming the absorptive capacity of enterocytes derived from these cells; however, this model is unproven and controversial. Hepcidin, a peptide hormone (HAMP; OMIM 606464), seems to act in the same regulatory pathway as HFE. Although expression of mouse Hamp is normally greater during iron overload, Hfe-/- mice have inappropriately low expression of Hamp. We crossed Hfe-/- mice with transgenic mice overexpressing Hamp and found that Hamp inhibited the iron accumulation normally observed in the Hfe-/- mice. This argues against the crypt programming model and suggests that failure of Hamp induction contributes to the pathogenesis of hemochromatosis, providing a rationale for the use of HAMP in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704388     DOI: 10.1038/ng1150

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  93 in total

1.  A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

Authors:  Thomas B Bartnikas; Mark D Fleming
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 2.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

Review 3.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 4.  Hepcidin and its role in iron absorption.

Authors:  K J Robson
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 5.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

6.  Of mice and men: the iron age.

Authors:  Sophie Vaulont; Dan-Qing Lou; Lydie Viatte; Axel Kahn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia.

Authors:  H Kulaksiz; S G Gehrke; A Janetzko; D Rost; T Bruckner; B Kallinowski; W Stremmel
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 9.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

Review 10.  The role of hepcidin in iron metabolism.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.